Virabhak, Suchin <br/><br/>
Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan.  [electronic resource] 

 -  Journal of medical economics  Dec 2016 
 - 1144-1156 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.1080/13696998.2016.1206908  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anilides--economics<br/>Antiviral Agents--economics<br/>Carbamates--economics<br/>Cost-Benefit Analysis<br/>Cyclopropanes<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--drug effects<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Japan<br/>Lactams, Macrocyclic<br/>Macrocyclic Compounds--economics<br/>Male<br/>Middle Aged<br/>Models, Economic<br/>Proline--analogs & derivatives<br/>Ritonavir--economics<br/>Sulfonamides<br/>Valine